Research Analysts Offer Predictions for Ardelyx Q2 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for Ardelyx in a report released on Wednesday, June 18th. HC Wainwright analyst M. Caufield forecasts that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.63 EPS and FY2029 earnings at $1.15 EPS.

ARDX has been the subject of several other research reports. Raymond James Financial cut shares of Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 price target for the company. in a report on Friday, May 2nd. BTIG Research assumed coverage on shares of Ardelyx in a research report on Tuesday, March 4th. They set a “buy” rating and a $14.00 price objective for the company. Cantor Fitzgerald upgraded shares of Ardelyx to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank began coverage on Ardelyx in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Finally, Citigroup lowered their price objective on Ardelyx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.89.

Ardelyx Stock Up 1.4%

ARDX stock opened at $3.68 on Monday. The company’s 50 day moving average price is $4.06 and its 200 day moving average price is $4.79. The firm has a market capitalization of $880.48 million, a price-to-earnings ratio of -16.73 and a beta of 0.59. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $8.06. The company has a debt-to-equity ratio of 1.04, a quick ratio of 3.81 and a current ratio of 4.12.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). The company had revenue of $74.11 million during the quarter, compared to analyst estimates of $79.40 million. Ardelyx had a negative net margin of 14.86% and a negative return on equity of 34.45%. Ardelyx’s revenue for the quarter was up 61.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.11) EPS.

Hedge Funds Weigh In On Ardelyx

Institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in Ardelyx by 13.3% during the 4th quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company’s stock worth $123,587,000 after purchasing an additional 2,858,061 shares during the period. Vanguard Group Inc. raised its holdings in shares of Ardelyx by 4.4% in the first quarter. Vanguard Group Inc. now owns 14,997,234 shares of the biopharmaceutical company’s stock valued at $73,636,000 after buying an additional 634,575 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Ardelyx by 118.2% during the first quarter. Millennium Management LLC now owns 6,465,262 shares of the biopharmaceutical company’s stock worth $31,744,000 after buying an additional 3,501,782 shares during the period. Geode Capital Management LLC grew its holdings in shares of Ardelyx by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,730 shares of the biopharmaceutical company’s stock worth $27,941,000 after buying an additional 21,988 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Ardelyx during the first quarter worth about $16,735,000. 58.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Ardelyx news, CFO Justin A. Renz sold 7,218 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total value of $29,449.44. Following the completion of the sale, the chief financial officer now owns 416,089 shares in the company, valued at approximately $1,697,643.12. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott acquired 381,377 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was purchased at an average cost of $4.22 per share, with a total value of $1,609,410.94. Following the completion of the acquisition, the director now directly owns 2,396,871 shares of the company’s stock, valued at approximately $10,114,795.62. This trade represents a 18.92% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 881,377 shares of company stock worth $3,402,411 and have sold 166,809 shares worth $708,914. 4.80% of the stock is owned by company insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.